191 related articles for article (PubMed ID: 24550338)
1. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
Babakhani F; Seddon J; Sears P
Antimicrob Agents Chemother; 2014 May; 58(5):2934-7. PubMed ID: 24550338
[TBL] [Abstract][Full Text] [Related]
2. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
3. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Babakhani F; Gomez A; Robert N; Sears P
Antimicrob Agents Chemother; 2011 Sep; 55(9):4427-9. PubMed ID: 21709084
[TBL] [Abstract][Full Text] [Related]
4. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
Allen CA; Babakhani F; Sears P; Nguyen L; Sorg JA
Antimicrob Agents Chemother; 2013 Jan; 57(1):664-7. PubMed ID: 23147724
[TBL] [Abstract][Full Text] [Related]
5. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
Shah D; Dang MD; Hasbun R; Koo HL; Jiang ZD; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 May; 8(5):555-64. PubMed ID: 20455684
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis.
Artsimovitch I; Seddon J; Sears P
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S127-31. PubMed ID: 22752861
[TBL] [Abstract][Full Text] [Related]
7. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.
Babakhani F; Seddon J; Robert N; Shue YK; Sears P
Antimicrob Agents Chemother; 2010 Jun; 54(6):2674-6. PubMed ID: 20308366
[TBL] [Abstract][Full Text] [Related]
8. Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species.
Jung E; Kraimps A; Dittmann S; Griesser T; Costafrolaz J; Mattenberger Y; Jurt S; Viollier PH; Sander P; Sievers S; Gademann K
Chembiochem; 2023 Dec; 24(24):e202300570. PubMed ID: 37728121
[TBL] [Abstract][Full Text] [Related]
9. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Caspers P; Bruyère T; Schroeder S; Pfaff P; Knezevic A; Keck W; Ritz D
Antimicrob Agents Chemother; 2014; 58(2):901-8. PubMed ID: 24277035
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activities of fidaxomicin.
Goldstein EJ; Babakhani F; Citron DM
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S143-8. PubMed ID: 22752863
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
[TBL] [Abstract][Full Text] [Related]
12. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Babakhani F; Gomez A; Robert N; Sears P
J Med Microbiol; 2011 Aug; 60(Pt 8):1213-1217. PubMed ID: 21349983
[TBL] [Abstract][Full Text] [Related]
13. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
Carman RJ; Boone JH; Grover H; Wickham KN; Chen L
Antimicrob Agents Chemother; 2012 Nov; 56(11):6019-20. PubMed ID: 22908175
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence.
Goldstein EJ; Citron DM; Tyrrell KL
Antimicrob Agents Chemother; 2014; 58(2):1187-91. PubMed ID: 24247123
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
16. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.
Miller MA; Blanchette R; Spigaglia P; Barbanti F; Mastrantonio P
J Clin Microbiol; 2011 Dec; 49(12):4319-21. PubMed ID: 21998414
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin: a review of its use in patients with Clostridium difficile infection.
Scott LJ
Drugs; 2013 Oct; 73(15):1733-47. PubMed ID: 24136090
[TBL] [Abstract][Full Text] [Related]
18. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
Cao X; Boyaci H; Chen J; Bao Y; Landick R; Campbell EA
Nature; 2022 Apr; 604(7906):541-545. PubMed ID: 35388215
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
[TBL] [Abstract][Full Text] [Related]
20. Fecal transplantation therapy for Clostridium difficile-associated pouchitis.
Patel LN; Schairer J; Shen B
Int J Colorectal Dis; 2014 Feb; 29(2):263-4. PubMed ID: 24132529
[No Abstract] [Full Text] [Related]
[Next] [New Search]
